Author:
Durán C. E.,Bustamante M.,Barbosa M.,Useche E. M.,Triviño J.,Sandoval L.,Moncayo P. A.,Rivas A. M.,Zapata J. S.,Hernández Quintero J. D.,Meza S.,Bolaños J. S.,Schweineberg J.,Mesa L.,Posada J. G.
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Carey, R. M. et al. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension. 72(5), E53-90 (2018).
2. Rimoldi, S. F., Messerli, F. H., Bangalore, S. & Scherrer, U. Resistant hypertension: What the cardiologist needs to know. Eur. Heart J. 36(40), 2686–2695 (2015).
3. Noubiap, J. J. et al. Global prevalence of resistant hypertension: A meta-analysis of data from 3.2 million patients. Heart. 105(2), 98–105 (2019).
4. Nishimoto, K. et al. Diverse pathological lesions of primary aldosteronism and their clinical significance. Hypertens. Res. 44(5), 498–507 (2021).
5. Meng, Z. et al. Long-term mortality for patients of primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 10(11), 510888 (2020).